A Phase Ib Study of AEB071 and MEK162 in Patients with Advanced Uveal Melanoma

Full Title
A Phase Ib/II, Open-label, Multicenter Study of AEB071 and MEK162 in Adult Patients with Metastatic Uveal Melanoma

AEB071 is an investigational drug that works by blocking an enzyme called protein kinase C (PKC). PKC is important for the growth of uveal melanoma (a cancer of the eye). MEK162 is an investigational drug that inhibits a protein called MEK1/2, which drives cancer growth. It has been shown to be active in some patients with melanoma of the skin, but has not yet been assessed in patients with uveal melanoma. Both AEB071 and MEK162 are taken orally (by mouth).

In this study, researchers want to find the highest doses of AEB071 and MEK162 that can be given when both drugs are used together in patients with uveal melanoma that has spread (metastasized) to other parts of the body. There are very few existing treatments that have been found to slow the growth of metastatic uveal melanoma.


To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have metastatic uveal melanoma.
  • Patients should have recovered from the serious side effects of previous therapies.
  • This study is open to patients ages 18 and older.

For more information and to inquire about eligibility for this study, please contact Dr. Michael Postow at 646-888-4589.

Melanoma: Melanoma of the Eye
Related Diseases